Elevance Health
ELV
425.35
+11.60
+2.80%
Elevance Health
US · ELV
#242 by market cap
Listed 1970
425.35
+11.60
+2.80%
Live - 5344 symbols - heartbeat 177s ago
· 2026-11-04 09:50
Analyst consensus 13 analysts
Buy
Avg price target 481.75 +13.3%
Price target rangecurrent 425.35
Low449.00
Avg481.75
High523.00
Buy 69%
Hold 31%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-23 | TD Cowen | -- | Buy | 495.00 |
| 2026-10-23 | Mizuho Securities | -- | Buy | 490.00 |
| 2026-10-22 | UBS | -- | Buy | 523.00 |
| 2026-10-22 | BofA Securities | -- | Buy | 500.00 |
| 2026-10-22 | Truist Financial | -- | Buy | 500.00 |
| 2026-10-22 | Morgan Stanley | -- | Hold | 449.00 |
| 2026-10-22 | Goldman Sachs | -- | Hold | 451.00 |
| 2026-10-22 | Barclays | -- | Buy | 472.00 |
| 2026-10-21 | Wells Fargo | -- | Buy | 473.00 |
| 2026-10-21 | BofA Securities | -- | Buy | 480.00 |
| 2026-10-21 | Guggenheim | -- | Buy | 485.00 |
| 2026-10-21 | RBC Capital | -- | Hold | 455.00 |
| 2026-10-12 | Guggenheim | -- | Buy | 460.00 |
| 2026-10-07 | Barclays | -- | Buy | 469.00 |
| 2026-10-07 | RBC Capital | -- | Hold | 424.00 |
| 2026-10-05 | Bernstein | -- | Buy | 488.00 |
| 2026-09-18 | UBS | -- | Buy | 460.00 |
| 2026-09-15 | Wells Fargo | -- | Buy | 473.00 |
| 2026-09-11 | BofA Securities | -- | Buy | 480.00 |
| 2026-09-11 | Barclays | -- | Buy | 457.00 |
| 2026-09-09 | Bernstein | -- | Buy | 488.00 |
| 2026-09-04 | Bernstein | -- | Buy | 488.00 |
| 2026-08-28 | Bernstein | -- | Buy | 488.00 |
| 2026-08-20 | Argus Research | -- | Hold | -- |
| 2026-08-14 | Bernstein | -- | Buy | 488.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C+
Momentum strategy signal
Buy
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: BofA Securities moved from Hold to Buy on 2026-04-29.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-29 | BofA Securities | Hold → Buy | 435.00 |
| 2026-02-03 | RBC Capital | Buy → Hold | 358.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-15 | -- | ±5.36% | -8.54% (beat) |
| 2026/Q1 | 2026-04-22 | -- | ±7.73% | +0.03% (in line) |
| 2025/Q4 | 2026-01-28 | -- | ±8.09% | +5.86% (in line) |
| 2025/Q3 | 2025-10-21 | -- | ±9.77% | -1.22% (in line) |
| 2025/Q2 | 2025-07-17 | -- | ±8.10% | -12.22% (beat) |
| 2025/Q1 | 2025-04-22 | -- | ±8.98% | +2.26% (in line) |
| 2024/Q4 | 2025-01-23 | -- | ±9.97% | +2.72% (in line) |
| 2024/Q3 | 2024-10-17 | -- | ±6.12% | -10.59% (beat) |
| 2024/Q2 | 2024-07-17 | -- | ±3.86% | -5.82% (beat) |
| 2024/Q1 | 2024-04-18 | -- | ±4.95% | +3.19% (in line) |
| 2023/Q4 | 2024-01-24 | -- | ±4.20% | +0.32% (in line) |
| 2023/Q3 | 2023-10-18 | -- | ±4.17% | +0.78% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-04 09:50:11 · For reference only, not investment advice and not tailored to your situation.
Elevance Health discussion 0 comments